{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.0","upperLimit":"67.0","value":"53.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"description":"As the median overall survival has not been reached, the data for the landmark analysis at 24 months are provided.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ibrutinib (I): I 840 mg orally, once daily continuously starting day 1 of Cycle (C) 1 until confirmed disease progression, unacceptable toxicity or other protocol specified reason for discontinuation Bortezomib (B): C 1-8: (21-day C): B 1.3 mg/m\\^2 sub-cutaneously on days 1, 4, 8, and 11 of each C C 9-12: (42-day C): B 1.3 mg/m\\^2 sub-cutaneously on days 1, 8, 22 and 29 of each C Dexamethasone (D): C 1-8: (21-day C): D 20 mg orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of each C C 9-12: (42-day C): D 20 mg orally on days 1, 2, 8, 9, 22, 23, 29 and 30 of each C C 13+ (28-day C): D 40 mg orally once weekly Dose adjustment of D to 10 mg on days specified during C 1-12 and 20 mg weekly during C 13+ is recommended for subjects \\>75 years of age.\n\nFollowing implementation of Protocol Amendment 4, D administration was reduced to Days 1, 4, 8, and 11 during each 21-day C (C 1-8) and on Days 1, 8, 22 and 29 on each 42-day C (C 9-12) and unchanged thereafter","id":"OG000","title":"Ibrutinib+ Bortezomib+ Dexamethasone"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"The median time on study was 19.6 months (0.16+, 24.64), with the 24 month Overall Survival (OS) rate presented based on Kaplan-Meier estimates.","title":"Overall Survival (OS) at 24 Months","type":"SECONDARY","unitOfMeasure":"percentage of participants"}